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and TS. T1DM and T2DM-n.i reported better values of HRQoL
and T2DM-n.i better TS.
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OBJECTIVES: Patients play a major role in the management of
type 2 diabetes since this depends not only on medication but
also on behavioural modiﬁcations in areas such as nutrition,
physical activities and weight loss. Therefore, patients’ under-
standing of the disease and its management are particularly
important to ensure high compliance and reduce risk of late
complications. The aim of this project was to develop a tool for
clinical practice to 1) renew patient-clinician communication on
type 2 diabetes management; 2) reinforce patients’ motivation
by rectifying or perfecting their knowledge; and 3) agree
achievable micro-objectives between patients and clinicians.
METHODS: Face-to-face semi-structured interviews were con-
ducted with 10 adult type 2 diabetes patients by a psychologist
in parallel with interviews with 5 general practitioners,
involved in the management of type 2 diabetic patients. All
interviews were recorded and transcribed, in order to analyse
the content and organise it by domains. Based on these ﬁndings
and on feedback from experts, a ﬁrst version of the tool was
developed. This was tested using a cognitive interview method
with 5 type 2 diabetics, to assess the clarity, comprehension,
and relevance of each item as well as the overall acceptability
of the tool. RESULTS: Five major domains were identiﬁed as
playing a role in type 2 diabetes disease management: physical
activities, treatment, nutrition, knowledge of the disease and
knowledge of glycaemia issues. A speciﬁc module was devel-
oped around each of the 5 domains, drafting items using
patients’ verbatim expressions. The tool allows patients to
describe their beliefs, attitudes and priorities. The tool was
revised after the patient tests. CONCLUSIONS: This tool
should enhance patient-clinician communication on diabetes
management. By revealing patients’ beliefs, identifying their
goals, triggering positive changes, this tool could help clinicians
with the therapeutic education of patients. It will be tested in a
speciﬁc validation study.
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OBJECTIVES: Diabetes is a common, debilitating chronic illness
with multiple impacts on patients’ lives. Critical to understand-
ing these impacts is the effect of the treatment delivery system. In
diabetes multiple systems are available; however, a patient
reported outcomes (PRO) measure assessing impacts appropriate
for all systems is not available. As a result, impacts can’t be
compared across treatments and clinical decisions targeting treat-
ments to patient needs is hampered. A well developed PRO
measure appropriate across delivery systems is critical for future
research. The purpose of the study was to understand the full
spectrum of PRO issues and develop a measure of these impacts
across all delivery systems. METHODS: Qualitative data was
collected from literature, experts and patients and transcripts
thematically coded. Additionally, validation ﬁndings from four
previously developed diabetes PRO measures (ITSQ, Diab-
MedSat, Diabetes Productivity, Diabetes Symptom) were exam-
ined for relevance. Based on a synthesis of all information, a
conceptual model of the impact of treatment applicable to all
delivery systems was developed and a PRO measure generated.
RESULTS: A total of 143 patients in three countries (US, UK,
Australia) treated with the full range of treatment options (oral,
syringe, pen, inhaled, pump) were interviewed regarding the
impact of diabetes treatment on functioning, well-being and
health. Regardless of delivery system, common impacts of dia-
betes treatment were identiﬁed: psychological health, daily life
interference (home/work), treatment burden, device satisfaction,
perceived efﬁcacy and side effects. Key modiﬁers to this impact
(i.e., treatment history, occupation, activity level) and conse-
quences (i.e., compliance, poor productivity) were also identiﬁed.
Based on the conceptual model, a PRO impact measure (TRIM-
Diabetes) was generated with six discrete domains. CONCLU-
SIONS: The instrument development process, the full conceptual
model, and discussion of clinical implications will be presented.
This information should help clinicians identify key PRO issues
for diabetes, facilitate targeted treatments and allow for mean-
ingful measurement of treatment effect regardless of treatment
delivery system.
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OBJECTIVES: To develop concepts, domains and items for a
patient-reported outcome proﬁle measure that addresses the
behaviors, attitudes, and importance of self-managing diabetes in
patients with type 2 diabetes. This self-management proﬁle
complements traditional clinical outcomes to evaluate how
diabetes treatments improve self-management behaviors.
METHODS: We developed a conceptual model and conceptual
framework of patient self-management to support a patient-
reported self-management proﬁle. These models incorporate
treatment attributes identiﬁed through qualitative interviews
with patients and the review of the American Diabetes Associa-
tion (ADA) 2008 Standards of Medical Care in Diabetes. The
proﬁle consists of items measuring patient behaviors, feelings,
and attitudes about the importance of managing their blood
glucose, medication regimen, weight, eating, exercise, and
diabetes-related distress. Qualitative interviews were conducted
with patients with Type 2 diabetes managed with combinations
of lifestyle, oral and injectable therapy. Subjects were asked to
provide information on their most positive and problematic
experiences with treatment for their diabetes and their efforts to
manage their condition. Qualitative transcripts were coded by
like concepts and used with the ADA Standards to generate items
and develop the self management proﬁle. Additional patients
participated in cognitive interviews to address relevance and
clarity of items. RESULTS: Patients were enrolled from clinics
across the United States. Participants in the concept elicitation
interviews (n = 82) were 30–85 years of age (mean = 57.5);
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